> top > docs > PubMed:33113325 > annotations

PubMed:33113325 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 1050-1057 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T2 1050-1057 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T3 1864-1871 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T4 1864-1871 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-167 Sentence denotes Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris®) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series.
T2 168-181 Sentence denotes INTRODUCTION:
T3 182-377 Sentence denotes Severe coronavirus disease 2019 (COVID-19) is characterised by hyperinflammatory state, systemic coagulopathies, and multiorgan involvement, especially acute respiratory distress syndrome (ARDS).
T4 378-585 Sentence denotes We here describe our preliminary clinical experience with COVID-19 patients treated via an early initiation of extracorporeal blood purification combined with systemic heparinisation and respiratory support.
T5 586-594 Sentence denotes METHODS:
T6 595-695 Sentence denotes Fifteen patients were included; several biomarkers associated with COVID-19 severity were monitored.
T7 696-919 Sentence denotes Personalised treatment was tailored according to the levels of interleukin (IL)-6, IL- 8, tumour necrosis factor alpha, C-reactive protein (CRP), neutrophilto- lymphocyte ratio, thrombocyte counts, D-dimers, and fibrinogen.
T8 920-1109 Sentence denotes Treatment consisted of respiratory support, extracorporeal blood purification using the AN69ST (oXiris®) hemofilter, and 300 U/kg heparin to maintain activation clotting time ≥ 180 seconds.
T9 1110-1118 Sentence denotes RESULTS:
T10 1119-1301 Sentence denotes Ten patients presented with severe to critical disease (dyspnoea, hypoxia, respiratory rate > 30/min, peripheral oxygen saturation < 90%, or > 50% lung involvement on X-ray imaging).
T11 1302-1450 Sentence denotes The median intensive care unit length of stay was 9.3 days (interquartile range 5.3-10.1); two patients developed ARDS and died after 5 and 26 days.
T12 1451-1629 Sentence denotes Clinical improvement was associated with normalisation (increase) of thrombocytes and white blood cells, stable levels of IL-6 (< 50 ng/mL), and a decrease of CRP and fibrinogen.
T13 1630-1641 Sentence denotes CONCLUSION:
T14 1642-1835 Sentence denotes Continuous monitoring of COVID-19 severity biomarkers and radiological imaging is crucial to assess disease progression, uncontrolled inflammation, and to avert irreversible multiorgan failure.
T15 1836-2054 Sentence denotes The combination of systemic heparin anticoagulation regimens and extracorporeal blood purification using cytokine-adsorbing hemofilters may reduce hyperinflammation, prevent coagulopathy, and support clinical recovery.
T1 0-167 Sentence denotes Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris®) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series.
T2 168-181 Sentence denotes INTRODUCTION:
T3 182-377 Sentence denotes Severe coronavirus disease 2019 (COVID-19) is characterised by hyperinflammatory state, systemic coagulopathies, and multiorgan involvement, especially acute respiratory distress syndrome (ARDS).
T4 378-585 Sentence denotes We here describe our preliminary clinical experience with COVID-19 patients treated via an early initiation of extracorporeal blood purification combined with systemic heparinisation and respiratory support.
T5 586-594 Sentence denotes METHODS:
T6 595-695 Sentence denotes Fifteen patients were included; several biomarkers associated with COVID-19 severity were monitored.
T7 696-919 Sentence denotes Personalised treatment was tailored according to the levels of interleukin (IL)-6, IL- 8, tumour necrosis factor alpha, C-reactive protein (CRP), neutrophilto- lymphocyte ratio, thrombocyte counts, D-dimers, and fibrinogen.
T8 920-1109 Sentence denotes Treatment consisted of respiratory support, extracorporeal blood purification using the AN69ST (oXiris®) hemofilter, and 300 U/kg heparin to maintain activation clotting time ≥ 180 seconds.
T9 1110-1118 Sentence denotes RESULTS:
T10 1119-1301 Sentence denotes Ten patients presented with severe to critical disease (dyspnoea, hypoxia, respiratory rate > 30/min, peripheral oxygen saturation < 90%, or > 50% lung involvement on X-ray imaging).
T11 1302-1450 Sentence denotes The median intensive care unit length of stay was 9.3 days (interquartile range 5.3-10.1); two patients developed ARDS and died after 5 and 26 days.
T12 1451-1629 Sentence denotes Clinical improvement was associated with normalisation (increase) of thrombocytes and white blood cells, stable levels of IL-6 (< 50 ng/mL), and a decrease of CRP and fibrinogen.
T13 1630-1641 Sentence denotes CONCLUSION:
T14 1642-1835 Sentence denotes Continuous monitoring of COVID-19 severity biomarkers and radiological imaging is crucial to assess disease progression, uncontrolled inflammation, and to avert irreversible multiorgan failure.
T15 1836-2054 Sentence denotes The combination of systemic heparin anticoagulation regimens and extracorporeal blood purification using cytokine-adsorbing hemofilters may reduce hyperinflammation, prevent coagulopathy, and support clinical recovery.

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 35-40 Body_part denotes Blood http://purl.org/sig/ont/fma/fma9670
T2 504-509 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T3 759-770 Body_part denotes interleukin http://purl.org/sig/ont/fma/fma86578
T4 772-774 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T5 779-781 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T6 827-834 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T7 856-866 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T8 874-885 Body_part denotes thrombocyte http://purl.org/sig/ont/fma/fma62851
T9 979-984 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T10 1050-1057 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T11 1266-1270 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T12 1520-1532 Body_part denotes thrombocytes http://purl.org/sig/ont/fma/fma62851
T13 1537-1554 Body_part denotes white blood cells http://purl.org/sig/ont/fma/fma62852
T14 1549-1554 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T15 1573-1575 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T16 1864-1871 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T17 1916-1921 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T18 1941-1949 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 35-40 Body_part denotes Blood http://purl.obolibrary.org/obo/UBERON_0000178
T2 504-509 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T3 979-984 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T4 1266-1270 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T5 1543-1548 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T6 1916-1921 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 120-128 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 189-213 Disease denotes coronavirus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T3 215-223 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 334-369 Disease denotes acute respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0006502
T5 340-369 Disease denotes respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0009971
T6 371-375 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T7 436-444 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T8 662-670 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T9 1416-1420 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T10 1667-1675 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T11 1776-1788 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T12 1816-1834 Disease denotes multiorgan failure http://purl.obolibrary.org/obo/MONDO_0043726
T13 2010-2022 Disease denotes coagulopathy http://purl.obolibrary.org/obo/MONDO_0001531

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 35-40 http://purl.obolibrary.org/obo/UBERON_0000178 denotes Blood
T2 35-40 http://www.ebi.ac.uk/efo/EFO_0000296 denotes Blood
T3 95-96 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 139-140 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 504-509 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T6 504-509 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T7 779-784 http://purl.obolibrary.org/obo/CLO_0053704 denotes IL- 8
T8 979-984 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T9 979-984 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T10 1070-1080 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T11 1119-1122 http://purl.obolibrary.org/obo/CLO_0050884 denotes Ten
T12 1266-1270 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T13 1266-1270 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T14 1543-1554 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood cells
T15 1596-1597 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T16 1916-1921 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T17 1916-1921 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 772-774 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T3 779-781 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T5 809-814 Chemical denotes alpha http://purl.obolibrary.org/obo/CHEBI_30216
T6 827-834 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T7 1050-1057 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T8 1232-1238 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T9 1573-1575 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T11 1864-1871 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 793-801 http://purl.obolibrary.org/obo/GO_0070265 denotes necrosis
T2 793-801 http://purl.obolibrary.org/obo/GO_0019835 denotes necrosis
T3 793-801 http://purl.obolibrary.org/obo/GO_0008219 denotes necrosis
T4 793-801 http://purl.obolibrary.org/obo/GO_0001906 denotes necrosis
T5 1081-1089 http://purl.obolibrary.org/obo/GO_0050817 denotes clotting
T6 1776-1788 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2 120-128 Disease denotes COVID-19 MESH:C000657245
3 129-137 Species denotes Patients Tax:9606
35 189-213 Disease denotes coronavirus disease 2019 MESH:C000657245
36 215-223 Disease denotes COVID-19 MESH:C000657245
37 334-369 Disease denotes acute respiratory distress syndrome MESH:D012128
38 371-375 Disease denotes ARDS MESH:D012128
39 436-444 Disease denotes COVID-19 MESH:C000657245
40 445-453 Species denotes patients Tax:9606
41 546-560 Chemical denotes heparinisation
42 603-611 Species denotes patients Tax:9606
43 662-670 Disease denotes COVID-19 MESH:C000657245
44 759-777 Gene denotes interleukin (IL)-6 Gene:3569
45 779-784 Gene denotes IL- 8 Gene:3576
46 786-801 Disease denotes tumour necrosis MESH:D009336
47 816-834 Gene denotes C-reactive protein Gene:1401
48 836-839 Gene denotes CRP Gene:1401
49 908-918 Gene denotes fibrinogen Gene:2244
50 1050-1057 Chemical denotes heparin MESH:D006493
51 1123-1131 Species denotes patients Tax:9606
52 1157-1173 Disease denotes critical disease MESH:D016638
53 1175-1183 Disease denotes dyspnoea MESH:D004417
54 1185-1192 Disease denotes hypoxia MESH:D000860
55 1232-1238 Chemical denotes oxygen MESH:D010100
56 1397-1405 Species denotes patients Tax:9606
57 1416-1420 Disease denotes ARDS MESH:D012128
58 1425-1429 Disease denotes died MESH:D003643
59 1573-1577 Gene denotes IL-6 Gene:3569
60 1610-1613 Gene denotes CRP Gene:1401
61 1618-1628 Gene denotes fibrinogen Gene:2244
62 1667-1675 Disease denotes COVID-19 MESH:C000657245
63 1776-1788 Disease denotes inflammation MESH:D007249
64 1864-1871 Chemical denotes heparin MESH:D006493
65 2010-2022 Disease denotes coagulopathy MESH:D001778

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-167 Sentence denotes Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris®) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series.
T2 168-181 Sentence denotes INTRODUCTION:
T3 182-377 Sentence denotes Severe coronavirus disease 2019 (COVID-19) is characterised by hyperinflammatory state, systemic coagulopathies, and multiorgan involvement, especially acute respiratory distress syndrome (ARDS).
T4 378-585 Sentence denotes We here describe our preliminary clinical experience with COVID-19 patients treated via an early initiation of extracorporeal blood purification combined with systemic heparinisation and respiratory support.
T5 586-594 Sentence denotes METHODS:
T6 595-695 Sentence denotes Fifteen patients were included; several biomarkers associated with COVID-19 severity were monitored.
T7 696-919 Sentence denotes Personalised treatment was tailored according to the levels of interleukin (IL)-6, IL- 8, tumour necrosis factor alpha, C-reactive protein (CRP), neutrophilto- lymphocyte ratio, thrombocyte counts, D-dimers, and fibrinogen.
T8 920-1109 Sentence denotes Treatment consisted of respiratory support, extracorporeal blood purification using the AN69ST (oXiris®) hemofilter, and 300 U/kg heparin to maintain activation clotting time ≥ 180 seconds.
T9 1110-1118 Sentence denotes RESULTS:
T10 1119-1301 Sentence denotes Ten patients presented with severe to critical disease (dyspnoea, hypoxia, respiratory rate > 30/min, peripheral oxygen saturation < 90%, or > 50% lung involvement on X-ray imaging).
T11 1302-1450 Sentence denotes The median intensive care unit length of stay was 9.3 days (interquartile range 5.3-10.1); two patients developed ARDS and died after 5 and 26 days.
T12 1451-1629 Sentence denotes Clinical improvement was associated with normalisation (increase) of thrombocytes and white blood cells, stable levels of IL-6 (< 50 ng/mL), and a decrease of CRP and fibrinogen.
T13 1630-1641 Sentence denotes CONCLUSION:
T14 1642-1835 Sentence denotes Continuous monitoring of COVID-19 severity biomarkers and radiological imaging is crucial to assess disease progression, uncontrolled inflammation, and to avert irreversible multiorgan failure.
T15 1836-2054 Sentence denotes The combination of systemic heparin anticoagulation regimens and extracorporeal blood purification using cytokine-adsorbing hemofilters may reduce hyperinflammation, prevent coagulopathy, and support clinical recovery.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 279-293 Phenotype denotes coagulopathies http://purl.obolibrary.org/obo/HP_0003256
T2 340-360 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T3 786-792 Phenotype denotes tumour http://purl.obolibrary.org/obo/HP_0002664
T4 1175-1183 Phenotype denotes dyspnoea http://purl.obolibrary.org/obo/HP_0002094
T5 1185-1192 Phenotype denotes hypoxia http://purl.obolibrary.org/obo/HP_0012418
T6 2010-2022 Phenotype denotes coagulopathy http://purl.obolibrary.org/obo/HP_0003256